Diagnostic Performance of In-111 Capromab Pendetide SPECT/CT in Localized and Metastatic Prostate Cancer
- 1 October 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Nuclear Medicine
- Vol. 36 (10), 872-878
- https://doi.org/10.1097/rlu.0b013e318219ae29
Abstract
To determine the diagnostic performance of In-111 capromab pendetide single photon emission computed tomography/computed tomography (SPECT/CT), in the prostate gland, seminal vesicles, and lymph nodes via correlation to a gold standard of histopathology. In this study, we retrospectively reviewed all In-111 capromab pendetide SPECT/CT acquired at our institution for dedicated histopathology within a 4-month period. Statistical measures of performance were calculated in terms of glandular, seminal vesicle, and lymph node activity. The accuracies of glandular and seminal vesicle activity were then correlated to the indices of risk, including the stage, Gleason score, and prostate-specific antigen level, as well as the treatment history. Of the 200 scans meeting the criteria of our study, 197 had prostate gland histopathology, 94 had bilateral seminal vesicle histopathology, and 5 had a total of 43 resected lymph nodes for comparison. The overall accuracies of the scan results were determined to be 77.7% (area under the receiver operating characteristic curve [AUC] = 0.539) for the gland, 67.0% (AUC = 0.510) for the seminal vesicles, and 93.0% (AUC = 0.787) for lymph nodes. For glandular activity alone, scan accuracy was found to significantly improve with increasing Gleason score (P < 0.0001), and in a setting prior to treatment (P = 0.0005). No statistically significant differences were found between different scan groups with regards to seminal vesicle activity. The results of this study provide substantiating evidence In-111 capromab pendetide can be used to accurately diagnose lymph node metastases from primary cancers of the prostate; however, they also suggest the test may have limited utility in diagnosing tumors within the prostate gland and seminal vesicles.Keywords
This publication has 28 references indexed in Scilit:
- Imaging Prostate Cancer: A Multidisciplinary PerspectiveRadiology, 2007
- Imaging of Prostate CancerRadiologic Clinics of North America, 2007
- Technology Insight: monoclonal antibody imaging of prostate cancerNature Reviews Endocrinology, 2006
- Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer*Current Opinion in Urology, 2005
- Impact of Fusion of Indium-111 Capromab Pendetide Volume Data Sets with Those from MRI or CT in Patients with Recurrent Prostate CancerAmerican Journal of Roentgenology, 2004
- Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancerUrology, 1999
- Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastasesUrology, 1998
- Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell lineThe Prostate, 1997
- Upregulation of prostate-specific membrane antigen after androgen-deprivation therapyUrology, 1996
- Immunoscintigraphy of prostatic cancer: Preliminary results with 111in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356)The Prostate, 1991